Cargando…

Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial

Background: The rapid worldwide spread of the Omicron variant of SARS-CoV-2 has unleashed a new wave of COVID-19 outbreaks. The efficacy of molnupiravir, an approved drug, is still unknown in patients infected with the Omicron variant. Objective: Evaluated the antiviral efficacy and safety of molnup...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zou, Rongrong, Peng, Ling, Shu, Dan, Zhao, Lei, Lan, Jianfeng, Tan, Guoyu, Peng, Jinghan, Yang, Xiangyi, Liu, Miaona, Zhang, Chenhui, Yuan, Jing, Wang, Huxiang, Li, Song, Lu, Hongzhou, Zhong, Wu, Liu, Yingxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248931/ https://www.ncbi.nlm.nih.gov/pubmed/35784723 http://dx.doi.org/10.3389/fphar.2022.939573

Ejemplares similares

Efficacy and safety of molnupiravir in patients with Omicron variant vaccine breakthrough COVID-19 infection: a randomized, controlled trial
por: Liu, Yayun, et al.
Publicado: (2023)

Thymoquinone’s Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections
por: Lin, Dan-Yu, et al.
Publicado: (2023)

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
por: Li, Pengfei, et al.
Publicado: (2022)

Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model
por: Rosenke, Kyle, et al.
Publicado: (2022)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022)

Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters
por: Abdelnabi, Rana, et al.
Publicado: (2022)

Immunological and metabolic characteristics of the Omicron variants infection
por: Geng, Jiejie, et al.
Publicado: (2023)

Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Disease Progression of Hospitalized Elderly Patients with Omicron BA.2 Treated with Molnupiravir
por: Liu, Yayun, et al.
Publicado: (2022)

Molnupiravir and Its Antiviral Activity Against COVID-19
por: Tian, Lili, et al.
Publicado: (2022)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
por: Yip, Ashley Jia Wen, et al.
Publicado: (2022)

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
por: Vangeel, Laura, et al.
Publicado: (2022)

Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
por: Weil, Clara, et al.
Publicado: (2023)

Analysis of 394 COVID-19 cases infected with Omicron variant in Shenzhen: impact of underlying diseases to patient’s symptoms
por: Zhang, Peiyan, et al.
Publicado: (2022)

Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic
por: Suzuki, Yasuhito, et al.
Publicado: (2022)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

A retrospective study of Pupingqinghua prescription versus Lianhuaqingwen in Chinese participants infected with SARS-CoV-2 Omicron variants
por: Dong, Yidan, et al.
Publicado: (2022)

Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model
por: Rosenke, Kyle, et al.
Publicado: (2022)

Treating SARS-CoV-2 Omicron variant infection by molnupiravir for pandemic mitigation and living with the virus: a mathematical modeling study
por: Zheng, Qinyue, et al.
Publicado: (2023)

543. Molnupiravir Maintains Antiviral Activity Against SARS-CoV-2 Variants In Vitro and in Early Clinical Studies
por: Grobler, Jay, et al.
Publicado: (2021)

A retrospective study of Reyanning mixture in elderly patients infected with SARS-CoV-2 Omicron variant
por: Liu, Changya, et al.
Publicado: (2023)

Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences
por: Singla, Shivali, et al.
Publicado: (2022)

On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia
por: Boretti, Alberto
Publicado: (2023)

Comparative neutralization profiles of naive and breakthrough infections with Delta, Omicron BA.1 and BA.2 variants of SARS-CoV-2
por: Yang, Yang, et al.
Publicado: (2022)

Interactive effect of booster vaccination and vitamin D status on antibody production of Omicron variant‐infected adults: A real‐world cohort study
por: Peng, Denggao, et al.
Publicado: (2023)

Virofree, an Herbal Medicine-Based Formula, Interrupts the Viral Infection of Delta and Omicron Variants of SARS-CoV-2
por: Doan, Ly Hien, et al.
Publicado: (2022)

Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19
por: McIntosh, John A., et al.
Publicado: (2021)

Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic
por: Khiali, Sajad, et al.
Publicado: (2022)

Antiviral Drugs and Vaccines for Omicron Variant: A Focused Review
por: Garg, Nidhi, et al.
Publicado: (2023)

Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery
por: Li, Xinlei, et al.
Publicado: (2021)

Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis
por: Huang, Chienhsiu, et al.
Publicado: (2023)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022)

Molnupiravir for COVID-19
Publicado: (2022)

Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees
por: YangYang, et al.
Publicado: (2022)

Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study
por: Wai, Abraham Ka-chung, et al.
Publicado: (2023)

Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses
por: Wang, Yining, et al.
Publicado: (2021)

An Engineered Cytidine Deaminase for Biocatalytic Production of a Key Intermediate of the Covid-19 Antiviral Molnupiravir
por: Burke, Ashleigh J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mj89nikgm0aiblv94pqprhaivp